LEADING THE CHANGE
IN TRANSFORMING HEALTHCARE

Greg Bullington, co-founder and Chief Executive Officer, has led all commercial aspects of company development since inception including clinical trial design and execution, peer-reviewed publication, product development, manufacturing, commercial launch and overall intellectual property strategy. To date, Greg has raised over $30 million in capital to drive the successful growth and development of the company.

Greg has extensive experience in the healthcare industry having led product commercialization and strategy engagements for a wide variety of companies in the biotech (novel immunotherapy), healthcare insurance, wellness and enterprise software sectors.

Greg began his career in professional services with the Audit & Assurance practice of Deloitte & Touche LLP. He continued his professional development as a management consultant with Lake Partners, a Seattle-based strategy firm. In 2006, Greg founded Forum Ventures, a technology commercialization consultancy focused on accelerating the growth of early and mid-stage technology companies.

Over the past 15 years, Greg has led engagements and worked with senior executive teams at over 50 companies ranging from Fortune 100 corporations to venture-backed and early stage startups as a consultant, advisor, and investor. Additionally, Greg has significant intellectual property expertise and is the first named inventor on 28 issued patents as well as over 50 pending US and international patent applications.

Dr. Richard Patton, co-founder and Medical Director, is a board-certified pathologist with more than 40 years of active practice experience. Recognizing the patient safety and financial implications of false positive blood cultures, he has long been interested in exploring opportunities to reduce contamination rates.

In 2006, Dr. Patton designed a clinical trial to test the effectiveness of Initial Specimen Diversion Technique (ISDT), an innovation that he conceived earlier in his career. The results of the trial were significantly positive and published in the peer-reviewed Journal of Clinical Microbiology.

Dr. Patton’s areas of expertise are clinical microbiology, gastrointestinal pathology, and cytopathology. He was the Chief of Pathology and Medical Director of Clinical Laboratories at Northwest Hospital, Seattle, Washington for four decades. He has served as a Laboratory Inspector, Washington State Commissioner, NW Regional Commissioner, and Accreditation and Complaints Committee Member for the College of American Pathologists Laboratory Accreditation Program.

Bob Gerberich, Chief Commercial Officer, is a results-driven global business leader with over 25 years of experience in the surgical and medical device segments of the life sciences market. As a senior sales and marketing executive, he has an exceptional track record of success building new markets and driving rapid commercial growth from product introduction through broad scale adoption. Bob joined Magnolia Medical Technologies as Chief Commercial Officer in April 2017. He is responsible for leading all commercial and customer facing functions of the company.

Most recently, Bob served as Vice President of Sales and Marketing and Vice President of Sales at Invuity, Inc. (NASDAQ: IVTY). Under his direct commercial leadership, Invuity transformed into a rapid growth direct sales-driven advanced surgical photonics company leading the advancement of open minimal access surgery. Bob led the company from a $3 million to $50 million revenue run rate, delivering 17 consecutive quarters of quarter-over-quarter sales growth. He also drove the creation, launch and implementation of strategic marketing and partnership programs. The commercial impact of these programs supported the successful Initial Public Offering (IPO) of the company in June of 2015.

Prior to Invuity, Bob served as President of UltraShape North America and Head of Global Sales for UltraShape Ltd (acquired by Syneron Medical Ltd. [NASDAQ: ELOS]), where he established the North American subsidiary for UltraShape and launched the first non-surgical focused ultrasound body sculpting technology in the world.

Before UltraShape, Bob was Vice President of Sales and Marketing and Vice President of Sales for Thermage, Inc. (now Solta Medical, a division of Valeant Pharmaceuticals [NYSE:VRX]), where he led the successful platform launch of a proprietary radio-frequency technology, creating a new market for non-invasive tissue tightening. He built a direct sales organization from the ground up and led the company from $0 to a $50 million revenue run rate.

Earlier in his career, Bob led dynamic and fast-growing sales organizations at several other medical device companies within the hospital markets including INAMED Aesthetics, acquired by Allergan (NYSE: AGN), LySonix Inc., acquired by Mentor Worldwide, division of J&J (NYSE: JNJ), Leibinger L.P. acquired by Stryker (NYSE: SYK)], and Davol Inc. Blood Mgmt. Group subsidiary of CR Bard (NYSE: BCR). Bob holds a BS. in Marketing from Illinois State University.

Matt Stuckert, Vice President of Sales, is a senior sales executive with almost twenty years of successful experience leading high performance sales teams, launching new medical devices, and creating new markets, including: ChloraPrep® skin antiseptics, StatLock® catheter securement devices, and other unique products focused in Infection Prevention, Vascular Access, and Surgery. Matt joined Magnolia Medical Technologies as Vice President of Sales in June 2017, and is responsible for the US Sales organization.

Most recently, Matt served as Vice President of Business Development for San Francisco-based startup Applied Silver, leading the market introduction of their innovative silver-ion technology for the antimicrobial treatment of healthcare textiles.

Prior to Applied Silver, Matt served as Director of Corporate Accounts at Becton Dickinson (BD) via their acquisition of CareFusion. As Director of Corporate Accounts, he drove business growth across seven matrixed business units, working with the most complex healthcare systems in the country. Prior to BD’s acquisition of CareFusion, Matt served as Vice President of Sales, Eastern US & Canada, Vascular & Surgical Products for both CareFusion and its parent-company, Cardinal Health. In this role, Matt led a sales and clinical organization of over 70 direct/indirect reports to deliver over $400M in revenue. During this time Matt was awarded Vice-President-of-the-Year honors multiple times.

Prior to CareFusion, Matt was a key member of the initial sales management team for Enturia (acquired by Cardinal Health) where he led the successful market launch of ChloraPrep®, a novel line of skin antiseptic products, from startup to over $200M in sales. Matt’s strong leadership and sales performance earned him Manager-of-the-Year honors multiple times. Enturia was sold to Cardinal Health for $500M in 2008.

Before Enturia, Matt was one of the first members of the sales organization for San Diego-based startup, Venetec Intl. where he played a key role in the successful market launch and creating a new market for StatLock®, a new line of catheter securement devices. Venetec was ultimately sold to C.R. Bard. Matt holds a BS degree from Pennsylvania State University.

Brad Nelson, Vice President of Marketing, is a senior marketing executive with twenty years of experience in medical device and life science automation. He has a proven track record leading global organizations in the development and commercialization of new technologies focused on improving human health.  Brad joined Magnolia Medical Technologies as Vice President of Marketing in September 2017, and is responsible for the Marketing and Product Management organizations.

Most recently, Brad served as Senior Director of Corporate Development and Strategy, and Director of Marketing, for Labcyte Inc. He led the expansion of the company into high growth markets, including genomic research and precision medicine, resulting in sustained 20% or greater annual revenue growth over seven years. As a customer focused leader Brad developed strategic partnerships with global pharmaceutical organizations which led to funding the development of novel technology that more than doubled the addressable market of Labcyte, while providing a lasting impact on drug discovery, development, and precision medicine markets.

Prior to Labcyte, Brad served as Director of Marketing for Agilent Technologies [NYSE:A], via their acquisition of Velocity11, where he led the strategic and downstream marketing for the organization’s portfolio of robotic life science instrumentation. His marketing and product management teams helped deliver an average of 40% annual revenue growth across global markets. During his tenure at Velocity11, Brad was the first member of the product management team and developed the organization from early stage to an industry success.  Brad led the product definition, development, and launch of the Bravo® liquid handler, which created a new market segment for automated liquid handling. He also led the development of the Velocity11 brand to one of the most recognized in life science automation, including recognition from both Inc 500 and Deloitte Fast 50 as one of the fastest growing companies in North America.

Earlier in his career, Brad worked in roles in Product Management and Design Engineering at Stryker Endoscopy [NYSE:SYK] where he led new product development for ear, nose, and throat surgery devices resulting in 25% annual growth and the launch of a new line of powered shaver instrumentation.  Brad holds a BS in Mechanical Engineering from Purdue University.

John Havard, Vice President of Product Development, has over 25 years of product development experience, in both managerial and engineering roles, in the medical, life science, and consumer industries. John joined Magnolia in September 2017 to build and lead the engineering/product development team.

Most recently, John was the Vice President of Engineering and CTO at Stratos Product Development, a medical and consumer product consultancy in Seattle. Over a ten-year period in this role, he worked with dozens of clients, including Google, Welch Allyn, Microsoft, Abbott Labs and several start-ups, overseeing the technical development and staffing of successful products spanning drug delivery, life science/medical diagnostics, handheld and wearable devices, industrial automation, and wireless technologies. John grew the core engineering team from twenty to sixty people, and he helped build and maintain an industry reputation for technical excellence and successful execution from initial concepts to manufactured products.

Prior to Stratos, John was co-founder of EnVision Instruments, a small self-funded startup to create optical instrumentation for the biotech industry. He was the lead engineer and development manager on their first product, a cell density probe that tracked cell growth in bio-fermentation. Following this, EnVision was purchased by Skymoon Ventures, became Finesse Solutions, and was ultimately acquired by Thermo Fischer Scientific [NYSE:TMO] in 2017.

John’s earlier career included engineering and development (through Stratos) with numerous clients, including Hewlett-Packard, Therus, and Apple, where he made important contributions to their R&D and new products. He is an inventor on four US patents, with one additional pending. John holds a Bachelor of Arts and Bachelor and Master of Engineering degrees from Dartmouth.